Compare Nuvalent Inc (NUVL) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Invesco Preferred ETF — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Invesco Preferred ETF trades at $10.79. The key difference: Nuvalent Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| NUVL | PGX | |
|---|---|---|
Market Cap | $9.81B | — |
Sector | Technology | — |
52-Week High | $123.96 | $11.87 |
52-Week Low | $72.16 | $10.81 |
Enterprise Value | $8.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
PGX trades at $10.79, down 0.64% on the day, with a bearish technical outlook from moving averages. The ETF shows neutral momentum oscillators. Recent corporate actions include scheduled dividends for mid-2026. News highlights institutional selling and concerns over the fund's risk-return profile in the preferred stock space.
The outlook remains cautious due to structural subordination risks and interest rate sensitivity. Analyst sentiment is negative, citing capped upside and full participation in downturns. Key risks include credit defaults and macroeconomic shifts affecting preferred securities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
